Margaret Stanley

Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.

S. Delany-Moretlwe, D. Kaslow, J. Schiller, 2022, Vaccine.

Clinical update

S. Garland, M. Pitts, K. Hertlein, 2022 .

IPVS policy statement. Equity in cervical cancer prevention: for all and not just for some

A. Moscicki, A. Giuliano, S. Garland, 2019, Papillomavirus research.

HPV vaccination of immunocompromised hosts

A. Moscicki, J. Palefsky, S. de Sanjosé, 2017, Papillomavirus research.

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – A meeting report

D. Watson-Jones, N. Mugo, C. Eklund, 2023, Preventive medicine reports.

Characterising the local immune responses in cervical intraepithelial neoplasia: a cross‐sectional and longitudinal analysis

M. Stanley, N. Coleman, Y. Woo, 2008, BJOG : an international journal of obstetrics and gynaecology.